Pancreatic tumors continue to be a challenge in modern oncology. Due to the asymptomatic nature of early stages, most cases are diagnosed in advanced stages. The five-year survival rate of patients does not even reach 10%, and up to half of patients with metastatic pancreatic cancer never make it to the second line of systemic therapy due to the rapid deterioration of their overall clinical condition. In a case study from her own practice, Dr. Marie Beneš Kočová from the Oncology Department of České Budějovice Hospital shared her…
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
